Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Severe COVID-19
NCT04377659Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2020
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2020; status: terminated.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04377659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377659.